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Abstract
AGS-004 consists of matured autologous dendritic cells co-electroporated with in vitro transcribed RNA
encoding autologous HIV antigens. In an open-label, single arm sub-study of AGS-004-003, AGS-004 was
administered monthly to suppressed participants who started antiretroviral therapy (ART) during acute HIV
infection. HIV-1 specific T cell responses were measured by multicolor flow cytometry after 3–4 doses. The
frequency of resting CD4+ T-cell infection (RCI) was measured by quantitative viral outgrowth assay. Parti-
cipants demonstrating increased immune response postvaccination were eligible for analytic treatment inter-
ruption (ATI). AGS-004 induced a positive immune response defined as ‡2-fold increase from baseline in the
number of multifunctional HIV-1 specific CD28+/CD45RA- CD8+ effector/memory cytoxic T-lymphocytes
(CTLs) in all six participants. All participants underwent ATI with rebound viremia at a median of 29 days.
Immune correlates between time to viral rebound and the induction of effector CTLs were determined. Baseline
RCI was low in most participants (0.043–0.767 IUPM). One participant had a >2-fold decrease (0.179–0.067
infectious units per million [IUPM]) in RCI at week 10. One participant with the lowest RCI had the longest
ATI. AGS-004 dendritic cell administration increased multifunctional HIV-specific CD28+/CD45RA- CD8+
memory T cell responses in all participants, but did not permit sustained ART interruption. However, greater
expansion of CD28-/CCR7-/CD45RA- CD8+ effector T cell responses correlated with a longer time to viral
rebound. AGS-004 may be a useful tool to augment immune responses in the setting of latency reversal and
eradication strategies.
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Introduction
G iven a rapidly expanding need for antiretroviraltherapy (ART) for HIV-infected individuals worldwide,
innovative therapies that control or cure HIV-1 infection are
needed. One approach is to strengthen and broaden HIV-
specific CD8+ T cell responses, based on the temporal as-
sociation between the appearance of HIV-specific CD8+
responses and viral decline during acute HIV infection
(AHI).1,2 One HIV therapeutic immunization strategy utilizes
monocyte-derived dendritic cells (MD-DCs) loaded ex vivo
with RNA encoding HIV antigens, as MD-DCs are potent
antigen-presenting cells and induce primary and secondary
immune responses in CD4+ and CD8+ T cells. This approach
can induce and increase antigen-specific T cell responses in
animal models and patients with chronic infections and
cancer.3 Further, HIV-1 peptide-loaded DCs administered to
HIV-infected individuals can induce some degree of HIV-
specific immunogenicity.3–7
AGS-004-003 was a randomized controlled trial of AGS-
004 on HIV RNA set point following analytic treatment in-
terruption (ATI) in chronically HIV-infected (CHI) partici-
pants.4,8 AGS-004 is an autologous DC therapy consisting of
matured patient-derived autologous DCs co-electroporated
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with in vitro transcribed RNA encoding HIV-1 Gag, Nef,
Rev, and Vpr amplified from participants’ pre-ART plasma
and RNA encoding human CD40 ligand (CD40 L). Auto-
logous DCs are matured ex vivo by sequential exposure to tumor
necrosis factor alpha (TNF-a), interferon gamma (IFN-c), and
PGE2 before adding the CD40 L adaptive signal. CD40 L is
employed to maximize DC antigen presentation9 and improve
immunopotency, by inducing secretion of interleukin (IL)-12, a
necessary cytokine for CD8+ T cell responses.10,11
In this sub-study, we evaluated AGS-004 in participants
who started ART during AHI, as immune-enhancing strate-
gies may be particularly suited to these individuals. ART
initiation during AHI can preserve HIV-1-specific CD4+ and
CD8+ T cell responses12 and limit the size of the latent res-
ervoir.13–17 Further, most individuals are infected with a
single or limited number of founder viruses18,19 and early
treatment minimizes virus evolution, as few variants escape
from CD8+ T cell pressure in the first weeks.18,20 The com-
bination of preserved cellular responses and limited viral
diversity in acutely treated individuals provides a unique
population for vaccination studies.
Materials and Methods
This was an open-label, two-site, single arm sub-study of
AGS-004 DC therapy in participants ages 18–59 years who
initiated ART within 45 days of AHI, defined as a negative or
indeterminate enzyme immunoassay or negative HIV RNA
test within 45 days of detectable plasma HIV RNA. Elig-
ibility included HIV RNA levels <50 copies/ml (c/ml) on
ART for at least 6 months, CD4+ nadir ‡200 cells/mm3,
baseline CD4+ count >400 cells/mm3, and a pre-ART frozen
plasma sample within 90 days of starting ART. AHI partic-
ipants received five monthly doses of AGS-004 (weeks 0, 4,
8, 12, and 16) while on ART (Fig. 1), with each dose con-
sisting of 1.2 · 107 DCs administered as three 0.2 ml intra-
dermal injections. Participants began ATI at *week 20 and
continued monthly AGS-004 dosing. In contrast to the parent
study in CHI participants,4 only AHI participants with a
positive CTL response postvaccination were eligible for
voluntary ATI. CD4+ counts and HIV RNA levels were
evaluated every 2 weeks following ATI. Restarting ART
could be triggered by CD4+ count <350 cell/mm3, >20%
decline in absolute CD4+ count or CD4+ count percentage,
confirmed HIV RNA level ‡10,000 c/ml, or participant re-
quest. Participants were followed through week 48 after the
last AGS-004 dose or ART reinitiation (Fig. 1). The Uni-
versity of North Carolina at Chapel Hill (UNC) and Duke
University Institutional Review Boards approved the study.
All participants provided written informed consent.
Autologous DCs used to produce AGS-004 have been
described.4 Monocytes are collected during leukapheresis
and differentiated in culture. Autologous pre-ART HIV RNA
encoding Gag, Nef, Vpr, and Rev (GNVR) is amplified and
co-electroporated with synthetic CD40 L RNA into mature
DCs.9 A reduced quantity of Nef RNA is used to preserve DC
functionality by minimizing HLA downregulation.21 Vpr
RNA is truncated due to its ability to inhibit production of IL-
1222 and reduce activation of antigen-specific memory and
recall CD8+ CTL responses.10,23,24
A second leukapheresis was collected before ATI for
immune monitoring purposes. Autologous DCs were again
co-electroporated with CD40 L RNA and GNVR, or with
CD40 L RNA, and each individual antigen RNA or with
CD40 L RNA and GFP RNA (DCs expressing green
fluorescent protein (GFP) served as control DCs). This
allows measurement of HIV-specific T cell responses
in vitro to the combination RNA antigen payload (GNVR),
to each individual HIV antigen (Gag, Nef, Vpr, or Rev) and
to control DC for six separate DC targets. Peripheral blood
mononuclear cells (PBMCs) were collected at baseline
(immediately before the first AGS-004 dose), and 1 month
after the third (week 12) or fourth dose (week 16), and
2 days after the fourth dose in one participant (51–102).
Given a limited number of PBMCs collected, cultures were
set up as individual wells and positive responses determined by
subtracting two times the total number of functional CD28+/
CD45RA- effector/memory CTL at baseline, from the total
number of functional CD28+/CD45RA- effector/memory
CTL measured in response to in vitro stimulation with DC
encoding each antigen.
To determine immune responses by multicolor flow cy-
tometry, PBMCs collected at baseline and after ‡3 immu-
nizations were cultured in vitro with autologous DCs as
described.10,25 PBMCs were labeled with BrdU (bromo-
deoxyuridine) to track CTL proliferation and cocultured
with autologous DC targets prepared as above. Autologous
DC targets for in vitro stimulation were either DCs co-
electroporated with CD40 L RNA and all antigens (GNVR)
or with DCs co-electroporated with CD40 L and each in-
dividual antigen. To determine background nonspecific
activation of in vitro CTL cultures, PBMCs at each time
point were stimulated with CD40 L DCs co-electroporated
with GFP RNA. GFP RNA was not included in the ad-
ministered product. Cocultures were incubated at 37C for
6 days. On day 6, each culture was restimulated with the
same autologous DCs used in the initial culture, anti-
CD107a antibody was added and cultures were incubated at
37C for 5 h. Viable cells were identified by staining for
viability using Live/Dead Fixable Dye (Invitrogen)
FIG. 1. Study schema. ART, antiretroviral therapy; ATI, analytic treatment interruption; BL, baseline leukapheresis; PS,
prescreen; S, screen.
treatment-related adverse events in the study; none >grade 1,
with mild injection site reactions the most common. No
participant discontinued or interrupted study treatment due to
adverse events.
Three participants (51–100, 51–102, and 54–100) received
AGS-004 DC therapy with all four RNAs (GNVR). Two
participants (54–101 and 54–102) received AGS-004 with
three RNAs, Gag, Nef, and Rev (GNR) as Vpr was not re-
covered in the pre-ART sample; one participant (54–104)
received AGS-004 with three RNAs, Gag, Vpr, and Rev
(GVR) as Nef was not recovered in the pre-ART sample.
Previous work demonstrated that in vitro priming with
postmatured DC co-electroporated with CD40 L RNA and
HIV RNA encoding specific target antigens expanded
multifunctional antigen-specific CTL, exhibiting a CD28+/
CD45RA- effector/memory phenotype.4,11,28 Similar DC
therapy administered to participants with metastatic renal cell
carcinoma showed a significant correlation between the ex-
pansion of functional CD28+/CD45RA- effector/memory
CTL and clinical outcomes.25 Therefore, our primary im-
mune end point focused on the expansion of functional HIV-
1-specific CD28+/CD45RA- effector/memory CTLs.
After in vitro stimulation, the number of CD8+ T cells
expressing each functional marker was calculated at baseline
(W0, pre-AGS-004) and after AGS-004 administration (W12
or W16) for each participant (Fig. 3). Statistically significant
increases in the number of CD8+ T cells proliferating (BrdU)
and expressing IFN-c, CD107a and Grb were detected to the
total GNVR total RNA payload after AGS-004 admin-
istration in all six participants. The number of CD8+ T cells
expressing each functional marker (red dots) for a represen-
tative participant is shown (Fig. 4A). Post-AGS-004, the
number of proliferating CTLs increased after in vitro resti-
mulation from 14,011 to 32,875 cells/ml. Increases in the
numbers of cells/ml were seen for the lytic markers CD107a
(6,467–20,478) and GrB (15,971–27,793) and for the cyto-
kines IFN-c (6,718–20,557) and TNF-a (517–806). For this
representative participant, IL-2 decreased from 7,307 cells/
ml at baseline to 4,285 cells/ml post-AGS-004. Moreover, the
majority of functional CTLs resided in the CD28+/CD5RA-
effector/memory CTL subset (Fig. 4A red dots). Given in-
creases in the number of functional CTL present in the
CD28+/CD45RA- CTL population, we determined func-
tional marker expression after AGS-004 administration as a
quantitative value (cells/ml) for CTLs in the CD28+/
CD45RA- effector/memory CTL subset. Determining chan-
ges in the number of cells/ml with functional activity in the
CD28+/CD45RA- effector/memory CTL subset from base-
line to post-treatment enables a direct comparison between
measurements performed within a single participant and be-
tween participants. Six of six participants had greater than a
two-fold increase in the total number of CD28+/CD45RA-
effector/memory CTLs expressing any functional marker
after post-AGS-004 (W12 or W16), and in five participants
the increases over baseline (W0) were statistically significant
(Fig. 4 B–F). While the increase in response for participant
054–104 (Fig. 4G) was not statistically significant, it was
greater than two-fold over baseline (from 30,613 cells/ml at
baseline to 95,709 cells/ml at week 12). This contrasted to
responses measured to GFP where only two participants,
054–101 and 054–102 (Fig. 4E, F, respectively) had statis-
tically significant increases in the total number of CD28+/
followed by surface staining with specific antibodies for 
CD28, CCR7, CD27, CD45RA, CD3, and CD8 expression. 
Cells were fixed, permeabilized, and DNase treated to de-
tect BrdU (BD biosciences). Intracellular staining for IFN-
c, TNF-a, IL-2, GrB, and BrdU was performed. Cells were 
transferred to BD TruCount Tubes for analysis on a BD 
LSRII cytometer, with 400,000–600,000 events collected 
per sample.
Viable CD3+CD8+ T cells were divided into either CD28 
receptor-positive or CD28 receptor-negative subsets. Bool-
ean gating was used to define the central memory (CM) ef-
fector memory (EM) and effector (E) CTL subsets defined by 
the expression of CD45RA, CCR7, and CD27 within the 
CD28 receptor-positive and CD28 receptor-negative CTL 
subsets (Fig. 2A). Within the CM, EM, and E CTL subsets, 
positive staining for cytokines (IFN-c, TNF-a, and IL-2), 
cytolytic markers (Granzyme B [GrB], CD107a, and prolif-
eration (BrdU) (Fig. 2B) identified functional marker ex-
pression. Increases in effector marker expression are reported 
as the absolute number of cells/ml determined using Tru-
Count Tubes (BD biosciences) during sample acquisition by 
flow cytometry. The number of cells/ml within a given gate is 
calculated as follows: (number of cellular events collected/
number of Trucount beads collected) · (Trucount bead con-
centration)/collected volume [lL]) · 1,000.
As in the parent study (AGS-004-003),4 a positive re-
sponse to AGS-004 was defined as >2-fold increase over 
baseline in the number of CD28+/CD45RA- effector/mem-
ory CTLs (cells/ml) exhibiting at least one effector function 
defined by the expression of IFN-c, TNF-a, IL-2, GrB, 
CD107a, or proliferation to the total HIV antigen payload 
(GNVR) present. Statistically significant differences between 
CD28+/CD45RA- effector/memory CTL responses at base-
line and after AGS-004 administration were determined us-
ing a two-tailed Student’s t-TEST. Correlates between time 
to viral rebound and change in the number of effector/
memory and effector multifunctional CTLs after AGS-004 
administration were determined by nonparametric bivariate 
Spearman’s Rho statistical analysis.
Plasma HIV RNA assays were performed by a single-copy 
assay (SCA), with two measurements at baseline and at 
weeks 10 and 16. An additional SCA was performed at week 
28 if HIV RNA remained undetectable during ATI. The 
frequency of resting CD4+ T cell infection (RCI) was mea-
sured by quantitative viral outgrowth assay (QVOA) as de-
scribed26,27 at baseline and pre-AGS-004 dosing and after 
three doses on ART (week 10). Correlation between time to 
viral rebound during ATI and RCI and CTL fold increase was 
assessed by Spearman correlation. In participant (51–102) 
with prolonged aviremia following rebound during the ATI 
period, antiretroviral drug testing was performed at McGill 
University and the UNC School of Pharmacy.
Results
Between June 2012 and January 2013, six male partici-
pants enrolled with a median age of 35 years (range 26–56; 
Table 1). At enrollment, the median CD4+ T cell count was 
618 cells/mm3 (range 397–937), and the median time from 
AHI diagnosis to ART initiation was 15 days (range 9–20). 
The median time from participant ART start date to enroll-

















































































































































































































































































































































































































































































































































































































































































































































CD45RA- effector/memory CTLs expressing any functional
marker after AGS-004 administration.
We then examined the multifunctionality of the response,
defined as an increase in at least two functional markers after
post-AGS-004. Five of six participants had statistically sig-
nificant increases in multiple functional markers with par-
ticipants 54–100 (Fig. 4J) and 54–102 (Fig. 4L) having
increases in all six functional markers. Participants 51–100
(Fig. 4H) and 51–102 (Fig. 4I) had statistically significant
increases in all functional markers excluding IL-2, and par-
ticipant 54–101 (Fig. 4K) had statistically significant in-
creases in the number of cells/ml expressing markers for
BrdU, CD107a, IFN-c, and TNF-a. Participant 54–104
(Fig. 4M) had increases in functional markers over baseline;
however, the only statistically significant change was de-
tected for CTLs that produced IL-2.
The increased numbers of CD28+/CD45RA- effector/
memory CTL (cells/ml) determined from pre- to post-AGS-
004 treatment for each functional marker was plotted versus
time to viral rebound and showed an inverse correlate be-
tween time to rebound and the magnitude of proliferating
CTL (q = -0.811 p = < .05 or CTL expressing Grb (q = -0.811
p = < .05) (Fig. 5A). If the CD28+/CD45RA- subset was
further sub-gated to include only CTL expressing CCR7, to
define CM CTL, additional inverse correlates were seen with
CTL expressing IFN-c (q = -0.927 p = < .007), and CD107a
(q = -0.927 p = < .007), BrdU (q = -0.927 p = < .007), and
GrB (q = -0.927 p = < .007) (Fig. 5B). This prompted analysis
of other CTL subsets defined by the absence of the CD28
receptor and CCR7, to see whether other functional subsets
correlated with time to viral rebound. Interestingly, the in-
crease in the number of functional CTL representative as
effector CTL defined as CD28-/CCR7-/CD45RA- positively
correlated with time to viral rebound (Table 1) for numbers of
CTL that are BrdU positive (q = 0.811 p = < .05) express
CD107a, (q = 0.927 p = < .007), IL-2 (q = 0.840 p = < .036), or
TNF-a (q = 0.927 p = < .007) (Fig. 5C). These data suggest
participants with the longest time to viral rebound accumu-
lated increased numbers of effector CTL in peripheral blood
with a concurrent decrease in numbers of CM CTL in the
periphery.
Evaluation of response to individual RNA antigens after
in vitro stimulation revealed an increase in total numbers of
CD28+/CD45RA- effector/memory CTLs expressing any
functional marker for each participant to each individual HIV
antigen (Fig. 6). All six participants had ‡2-fold increased
responses over baseline to Gag (range 310–11,323 cells/ml)
(Fig. 6A), and responses were multifunctional. The percent-
age of each functional marker within the total response to
Gag is represented for each participant (Fig. 6B). While all
participants contained multifunctional CTLs, there was no
clear pattern of functional marker expression across partici-
pants. In some cases the CTL population response to Gag
contained CTLs that proliferated (shown in blue), or pro-
duced cytokines IFN-c (purple) or TNF-a (orange), or IL-2
(light blue). Lytic activity was detected with GrB expression
in three participants (green) and CD107a (red) for all par-
ticipants.
The multifunctional responses to Nef (Fig. 6C) ranged
from 2,380 to 37,834 cells/ml. Proliferating CTLs were ob-
served in three participants and two of these participants






































































































































































































































































































































































































































































































































































































































































































































































































composition of responses were multifunctional with 051–100
containing CTL expressing CD107a, IFN-c, and IL-2, par-
ticipant 051–102 contained proliferating CTL and all six
functional markers, 054–100 contained proliferating CTL
and CD107a and GrB. 054–101 contained proliferating CTL
and CD107a, IFN-c, and TNF-a. 054–102 contained CTL
expressing all six functional markers (Fig. 6D).
Four participants tested for response to Vpr revealed re-
sponses over baseline ranging from 8 to 67,160 cells/ml and
were multifunctional for two participants (051–102 and 054–
104), expressing all six functional markers. Responses for
participants 051–100 and 054–100 were below 100 cells/ml
and more mono-functional with CTL expressing only IL-2,
(051–100) or IFN-c and TNF-a (054–100) (Fig. 6F).
Responses to Rev over baseline ranged from 2,950 to
76,429 cells/ml (Fig. 6G); all participants had CTLs that
expressed two functional markers. For participant 51–100,
the response was dominated by CTL expressing IFN-c, GrB,
and TNF-a, and for 051–102, the response contained prolif-
erating CTL and CD107a, GrB, and IFN-c. 051–100 con-
tained CTL expressing IL-2 and CD107a, 054–101 contained
proliferating CTL and IFN-c, CD017a, and TNF-a. Both
FIG. 3. CD8+ T cell responses in participants receiving AGS-004. Box and whisker plots show the distribution of the
number of CD8+ T cells (cells/ml) proliferating (BrdU), expressing IFN-c, CD107a, Grb, IL-2, or TNF-a determined before
or post AGS-004 administration for participants. Statistically significant differences between the GFP background response
(open bar and whisker plots) and the total antigen payload (GNVR)-specific response (red bar and whisker plots) are shown.
Statistically significant differences between the total antigen payload (GNVR) responses determined pre- and post-AGS-004
administration are shown. *p < .05; **p < .01. GNVR, Gag, Nef, Vpr, and Rev; NS, not statistically significant.
FIG. 4. Multifunctional immune responses to the total antigen RNA payload in participants treated with AGS-004. CD8 T
cell responses at baseline (W0) or after AGS-004 administration (W12 or W16) were measured after in vitro stimulation
with AGS-004 autologous DCs and functional marker expression was detected by multicolor flow cytometry. (A) Dot plot
overlays from one representative participant before AGS-004 administration (W0) and after AGS-004 administration (W12)
show the distribution of cellular events representing each functional marker (red dots) BrdU, CD107a, Grb, IFN-c, IL-2, and
TNF-a overlaid on the total CD8+ T cell population (blue dots) gated on the CD28 (y-axis) and CD45RA (x-axis) plots. The
numbers are representative of cells/ml expressing each functional marker (red dots). (B–G) The total number of CD28+/
CD45RA- CTL (cells/ml, Y-axis) expressing any functional marker after stimulation with DCs encoding GFP or the final
product HIV payload (GNVR, GNR, or GVR) was calculated at baseline (W0) and post-AGS-004 (W12 or W16). Total
numbers of cells/ml were determined by adding the numbers of cells/ml measured for each individual functional marker. (B)
51–100 to GNVR, (C) 51–102 to GNVR, (D) 54–100 to GNVR, (E) 54–101 to GNR, (F) 054–102 GNR, and (G) 054–104
to GVR. Statistically significant increases in the total number of cells/ml expressing functional markers over baseline are
shown. NS, not significant. The contribution of each functional marker (cells/ml, y-axis) within the total response at baseline
(W0) or post-AGS-004 (W12 or W16) for each participant is shown, (H) 51–100 to GNVR, (I) 51–102 to GNVR, ( J) 54–
100 to GNVR, (K) 54–101 to GNR, (L) 054–102 GNR, and (M) 054–104 to GVR. BrdU , CD107a , Grb , IFN-c ,
IL-2 , and TNF-a . Starred (*) markers indicate statistically significant increased CTL responses from pre- to post-AGS-
004 administration. GNR, Gag, Nef, and Rev; GVR, Gag, Vpr and Rev.
‰

054–102 and 054–104 contained CTL expressing all six
functional markers (Fig. 6H).
After confirming increases in the number of functional
CD28+/CD45RA- memory CTL responses post-treatment,
all participants underwent ATI. Figure 7 shows the time
course of CD4+ T cell counts and changes in viral load for
participants. Participants rebounded to ‡40 copies/ml at a
median of 29 days (range 13–55), with a median ATI of
66 days (range 33–280; Table 1). Three participants restarted
ART due to confirmed HIV RNA >10,000 c/ml, two restarted
due to a >20% decline in CD4+ count, and one restarted after
meeting both CD4+ and viral load criteria. The median ob-
served peak HIV RNA level following ATI was 21,650 c/ml
(range 3,290–287,000), and no symptoms consistent with
acute retroviral syndrome were observed. All participants
rapidly suppressed viremia after restarting pre-entry ART
regimens (Fig. 7); however, two had confirmed viremia
during follow-up with self-reported nonadherence to re-
sumed ART (54–101, 54–104).
In one participant (051–102), initial viral rebound to
>10,000 c/ml was followed by repeat viral load of 3,579 c/ml
and continued ATI. Due to prolonged aviremia (280 days)
following initial viral rebound in this participant, therapeutic
drug testing was performed for efavirenz, emtricitabine, and
tenofovir on stored samples obtained during ATI. Efavirenz
was not detected eight days following ATI and before viral
rebound, but detected from three subsequent stored samples
from separate time points over 3 months during the ATI;
tenofovir and emtricitabine were detected in the one sample
tested. This participant denied restarting ART, and had a
second viral rebound of 12,200 c/ml at day 280.
The frequency of RCI at pre-entry and pre-AGS-004
dosing was low in most participants, ranging 0.043–0.767
infected resting CD4+ cells per million (IUPM; Table 1), and
in comparison with participants treated during CHI.29 Time
to viral rebound was inversely correlated with RCI
(q = -0.84; p = .04). The only participant (054–100) with a
statistically significant decrease in RCI (2.5-fold from 0.179
IUPM at baseline to 0.067 IUPM at week 10)30 also had
increases in the total number of functional CD28+/CD45RA-
CTLs (Fig. 4D), and increases in CD28-/CCR7-/CD45RA-
CTLs after AGS-004 dosing, but did not have the longest
ATI. Increases were multifunctional in nature with CTLs
positive for all six functional markers (Fig. 4J). Participant
054–100 had increases in the number of CTL responding to
Gag (Fig. 6A, B), Nef (Fig. 6C, D), and Rev (Fig. 6G, H) and
the longest time to rebound (55 days, Table 1) with an ATI
duration of 90 days (Fig. 7C) in the absence of an HLA allele
associated with HIV control.31 Despite an increase in both
effector/memory and effector CTL responses, this participant
had the highest observed peak HIV RNA level off ART
(287,000 c/ml), but suppressed to <50 c/ml 4 weeks after
reinitiating ART.
The participant (54–101, Fig. 7D) with the lowest baseline
RCI (0.043 IUPM) rebounded at 49 days, but underwent ATI
for 151 days, reinitiating ART due to decline in CD4+ count
percentage (44.1%–33.8%). The peak observed HIV RNA
level during this participant’s ATI was 3,290 c/ml followed
by rapid suppression after restarting ART, but developed
subsequent viremia with reported nonadherence to ART.
This participant showed an increase in the total number of
functional CTL after AGS-004 administration (Fig. 4E) and
FIG. 5. Increased numbers of effector CTL within the
CD28-/CCR7-/CD45RA- CTL subset correlates with longer
time to viral rebound. CD8+ T cell responses at baseline (W0)
or after AGS-004 administration (W12 or W16) were mea-
sured after in vitro stimulation with AGS-004 autologous DCs
and functional marker expression was detected by multicolor
flow cytometry. (A) Absolute numbers of CTL (cells/mL) for
each effector marker (BrdU , CD107a :, Grb ,, IFN-c X,
IL-2 B, and TNF-a 6) were calculated by subtracting the
number of CTL determined at baseline (W0) from the number
of CTL determined after AGS-004 administration (W12 or
W16). Absolute numbers of CTL with effector marker ex-
pression for the CD28+/CD45RA- CTL subset (A), the
CD28+CCR7+CD27-CD45RA- CTL subset (B), and the
CD28-CCR7-CD45RA- CTL subset (C) were plotted versus
time to viral rebound (days) for each participant. For each
subset only those effector markers that had either a positive
correlate with time to viral rebound or an inverse correlate with
time to viral rebound are shown. Correlates were determined
by nonparametric bivariate Spearman’s Rho statistical analysis.
in the CD28-CCR7-CD45RA- effector CTL subset with a
multifunctional response to the total GNR HIV antigen
payload and to the individual antigens Gag (Fig. 6A), Nef
(Fig. 6C) and Rev (Fig. 6G).
HIV RNA measurement by SCA was detectable above 1 c/
ml in only one participant at one time point after dosing,
preventing assessment of the impact of AGS-004 on low-level
viremia. No association of virologic or T cell response was
observed with HLA type (data not shown).
Discussion
AGS-004 DC therapy administered to individuals who
started ART during AHI led to statistically significant
FIG. 6. Multifunctional im-
mune responses to the indi-
vidual HIV antigens present in
the administered AGS-004
payload. The total number of
CD28+/CD45RA- CTL (cells/
ml, X-axis) expressing the any
functional marker after in vitro
stimulation with DCs encod-
ing the single HIV antigens
are expressed as the values
(cells/ml) greater than twofold
over baseline. (A) Participant
responses to GAG, (C) par-
ticipant responses to Nef, (E)
participant responses to Vpr,
and (G) participant responses
to Rev. The percent contribu-
tion of each individual func-
tional marker to the total
response is represented by pie
charts for participant re-
sponses to (B) GAG, (D) Nef,
(F) Vpr, and (H) Rev. Pie
charts of representative re-
sponses to BrdU , CD107a ,
Grb , IFN-c , IL-2 ,
TNF-a are shown clock-
wise starting at 12 o’clock.
increases in HIV-specific CD28+/CD45RA- effector/mem-
ory CTL responses to the total antigen payload in five of six
participants. Further, increased responses could be detected
to single HIV antigens present in the payload. All six par-
ticipants had an increased response to Gag and Rev, five
participants had increased responses to Nef, and two partic-
ipants to Vpr. The induced responses to the total antigen
payload or the individual antigens displayed a multifunc-
tional phenotype characterized by CD28+/CD45RA- effec-
tor/memory CTL that proliferated, produced cytokines such
as IFN-c, IL-2, and TNF-a and exhibited markers of lytic
activity, a critical function necessary to kill virally infected
cells. Further, the expansion of multifunctional CD28-/
CCR7-/CD45RA- effector CTLs correlated with a longer
time to viral rebound during ATI.
We observed a significant association between reservoir
size measured by QVOA and time to rebound, supporting the
hypothesis that a replication competent reservoir in resting
CD4 cells fuels HIV rebound. Of note, the one participant
with a significant decline in RCI had the longest time to
rebound. Given concerns that even brief periods of viral re-
bound would be unacceptable among individuals treated
during AHI, conservative criteria for reinitiating ART re-
sulted in variability in the reason for reinitiation, and limited
our ability to determine correlations. Due to the small sample
size, comparison of immune responses and time to viremia
with CHI participants who received AGS-004 or other
acutely treated patients is limited.
We hypothesized that time to viral rebound in acutely
treated participants might be substantially delayed as re-
ported in other cohorts treated early following acquisi-
tion.12,32,33 However, despite expansion of multifunctional
CD28+/CD45RA- effector/memory CTL responses, ex-
tended viral control was not observed. A lack of delay in viral
rebound has been recently reported in a large cohort of par-
ticipants treated during AHI.34 In fact, an inverse correlate
with time to viral rebound was seen with expansion of both
effector/memory and central/memory CTLs. Unexpectedly, a
positive correlation between longer time to viral rebound and
expansion of multifunctional effector CTL defined by the
lack of CD28, CCR7, and CD45RA was observed in our
study. Taken together, these data suggest that a conversion of
AGS-004 induced CD28+/CCR7+/CD45RA- central/mem-
ory CTL toward multifunctional effector CTL may contrib-
ute to immunological control of viral rebound. This
hypothesis is supported by the observation that participants
with the longest time to viral rebound during ATI shifted
from central/memory multifunctional CTLs toward a more
differentiated effector CTL phenotype that maintained mul-
tifunctionality. The ability to convert expanded CM CTL to
effector CTL may be essential to an effective antiviral im-
mune response.
FIG. 7. Measurement of viral load and CD4 T cell counts in participants receiving AGS-004. Plasma HIV RNA levels
(red lines) and CD4 cell counts (blue lines) are shown for participants treated with AGS-004. The blue shaded areas indicate
the period of analytic treatment interruption (ATI) across study visits and overlying arrows indicate the duration of ATI
(days). AGS-004 administrations are denoted by black arrows. Participant 51–102 is not shown given drug monitoring
revealed ongoing ART administration during the ATI period. ART, antiretroviral therapy; PS, prescreen; S, screen.
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